Share

TransMedics Group Inc (TMDX.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 18 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Price-adjusted rating

Neutral

5-Year Return Est.

+72.8%

TMDX.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is simple: TransMedics compounds revenue above twenty percent while the economics of each incremental dollar deteriorate. Growth increasingly comes from flying organs rather than selling perfusion disposables - service revenue reached 41% of Q2 2026 sales - and that mix is asset-heavy, lower-margin and cash-hungry. The base case assumes 2026 is genuinely an investment trough rather than a structural ceiling: adjusted operating margin recovers from the guided 12.5%-14% toward the mid-twenties by 2030 as an already-built fleet amortizes across far more missions. Shareholders are paid by earnings compounding, not by re-rating.

Revenue near $1.6B by 2031 at roughly 24% implies about $290M of net income.
That supports approximately $7 of EPS; a 21x multiple anchors the path-end price near $147.
Cross-check: implied $6B enterprise value equals 3.7x sales, below today's 5.3x price-to-sales.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-16	32.2
Observed price	2021-09-20	29.4
Observed price	2021-10-14	27.9
Observed price	2021-10-18	26.3
Observed price	2021-11-07	31.9
Observed price	2021-11-23	22.0
Observed price	2021-12-09	22.8
Observed price	2021-12-17	20.7
Observed price	2021-12-21	21.0
Observed price	2022-01-10	17.19
Observed price	2022-01-14	16.51
Observed price	2022-02-03	14.52
Observed price	2022-02-23	12.58
Observed price	2022-02-27	18.04
Observed price	2022-03-15	17.76
Observed price	2022-03-23	24.4
Observed price	2022-04-04	27.6
Observed price	2022-04-16	23.0
Observed price	2022-04-28	21.9
Observed price	2022-05-06	27.6
Observed price	2022-05-18	27.3
Observed price	2022-05-30	29.4
Observed price	2022-06-11	25.9
Observed price	2022-06-27	32.1
Observed price	2022-07-13	31.6
Observed price	2022-07-21	35.2
Observed price	2022-07-25	34.5
Observed price	2022-08-06	47.9
Observed price	2022-08-18	46.5
Observed price	2022-09-07	54.2
Observed price	2022-09-11	55.0
Observed price	2022-09-27	40.1
Observed price	2022-10-09	40.6
Observed price	2022-10-25	47.5
Observed price	2022-11-02	46.4
Observed price	2022-11-14	57.5
Observed price	2022-11-22	57.6
Observed price	2022-12-04	62.7
Observed price	2023-01-01	59.4
Observed price	2023-01-05	54.6
Observed price	2023-01-09	53.6
Observed price	2023-01-25	67.0
Observed price	2023-02-10	63.7
Observed price	2023-02-14	67.9
Observed price	2023-03-06	80.9
Observed price	2023-03-10	71.5
Observed price	2023-03-26	75.5
Observed price	2023-04-11	71.4
Observed price	2023-04-15	67.4
Observed price	2023-04-23	86.9
Observed price	2023-05-09	75.5
Observed price	2023-05-25	71.3
Observed price	2023-06-02	74.1
Observed price	2023-06-14	81.8
Observed price	2023-06-26	80.0
Observed price	2023-07-16	93.2
Observed price	2023-08-01	93.9
Observed price	2023-08-09	64.7
Observed price	2023-08-25	62.5
Observed price	2023-09-02	67.9
Observed price	2023-09-06	65.0
Observed price	2023-09-26	54.9
Observed price	2023-09-30	54.1
Observed price	2023-10-20	41.4
Observed price	2023-10-28	37.6
Observed price	2023-11-13	59.6
Observed price	2023-11-21	67.9
Observed price	2023-12-07	75.1
Observed price	2023-12-11	71.9
Observed price	2023-12-27	80.5
Observed price	2024-01-04	75.1
Observed price	2024-01-20	84.2
Observed price	2024-02-13	85.5
Observed price	2024-02-17	89.6
Observed price	2024-02-21	87.0
Observed price	2024-02-25	79.5
Observed price	2024-03-24	71.0
Observed price	2024-04-05	85.0
Observed price	2024-04-21	85.7
Observed price	2024-04-29	97.3
Observed price	2024-05-07	127
Observed price	2024-05-19	138
Observed price	2024-06-04	134
Observed price	2024-06-16	143
Observed price	2024-07-06	151
Observed price	2024-07-10	139
Observed price	2024-07-30	138
Observed price	2024-08-03	150
Observed price	2024-08-07	146
Observed price	2024-08-27	176
Observed price	2024-08-31	166
Observed price	2024-09-08	140
Observed price	2024-09-28	158
Observed price	2024-10-14	134
Observed price	2024-10-18	127
Observed price	2024-10-30	81.9
Observed price	2024-11-11	89.1
Observed price	2024-11-23	76.9
Observed price	2024-12-09	69.8
Observed price	2024-12-21	62.0
Observed price	2025-01-06	75.6
Observed price	2025-01-18	57.1
Observed price	2025-01-26	61.0
Observed price	2025-02-07	72.6
Observed price	2025-02-19	79.4
Observed price	2025-03-07	67.5
Observed price	2025-03-23	70.7
Observed price	2025-03-31	67.3
Observed price	2025-04-04	67.7
Observed price	2025-04-24	94.2
Observed price	2025-05-02	90.0
Observed price	2025-05-14	122
Observed price	2025-05-22	123
Observed price	2025-06-11	143
Observed price	2025-06-15	142
Observed price	2025-06-19	124
Observed price	2025-07-09	126
Observed price	2025-07-21	104
Observed price	2025-08-06	119
Observed price	2025-08-14	130
Observed price	2025-09-07	105
Observed price	2025-09-11	117
Observed price	2025-09-19	122
Observed price	2025-10-09	113
Observed price	2025-10-13	112
Observed price	2025-10-29	134
Observed price	2025-11-14	115
Observed price	2025-11-26	146
Observed price	2025-11-30	149
Observed price	2025-12-16	125
Observed price	2026-01-01	122
Observed price	2026-01-13	143
Observed price	2026-01-17	143
Observed price	2026-01-21	134
Observed price	2026-02-14	131
Observed price	2026-03-02	147
Observed price	2026-03-10	131
Observed price	2026-03-26	102
Observed price	2026-03-30	94.3
Observed price	2026-04-15	116
Observed price	2026-04-23	113
Observed price	2026-05-13	64.2
Observed price	2026-05-17	66.6
Observed price	2026-05-25	70.1
Observed price	2026-06-18	78.8
Observed price	2026-06-30	66.4
Observed price	2026-07-04	70.0
Observed price	2026-07-16	76.0
Observed price	2026-07-28	76.3
Observed price	2026-08-13	89.6
Observed price	2026-08-21	94.8
Observed price	2026-09-02	84.3
Observed price	2026-09-22	88.1
Observed price	2026-09-24	83.9
Observed price	2026-09-25	85.3
Published advisor forecast	2026-09-18	86.4
Published advisor forecast	2026-12-18	81.2
Published advisor forecast	2027-03-18	86.9
Published advisor forecast	2027-06-18	91.3
Published advisor forecast	2027-09-18	87.6
Published advisor forecast	2027-12-18	94.6
Published advisor forecast	2028-03-18	100
Published advisor forecast	2028-06-18	95.3
Published advisor forecast	2028-09-18	102
Published advisor forecast	2028-12-18	108
Published advisor forecast	2029-03-18	113
Published advisor forecast	2029-06-18	118
Published advisor forecast	2029-09-18	113
Published advisor forecast	2029-12-18	120
Published advisor forecast	2030-03-18	126
Published advisor forecast	2030-06-18	131
Published advisor forecast	2030-09-18	127
Published advisor forecast	2030-12-18	134
Published advisor forecast	2031-03-18	139
Published advisor forecast	2031-06-18	143
Published advisor forecast	2031-09-18	147

2. Scenarios & Signals

Bull case

The decisive condition is the margin trough proving arithmetic rather than structural. If internal air coverage passes 90% while fleet depreciation spreads across a doubled mission count, incremental service margin turns sharply positive; that cash then funds OCS Kidney without dilution, and a second organ franchise resets the addressable market above 21,000 annual US cases. European tenders add a non-US vector. Earnings compound above thirty percent annually and the multiple expands instead of compressing.

Bear case

The trap springs if in-situ NRP scales faster than kidney arrives. NRP needs no TransMedics disposable and no TransMedics flight, so each converted centre removes both revenue legs at once. Add HRSA enforcement slowing DCD throughput and a 2028 convertible settled with equity below its conversion price, and a fixed-cost aviation base meets decelerating volume. Operating leverage inverts, free cash flow turns negative, and the multiple halves.

Current crowd narrative

The crowd has settled on one sentence: TransMedics broke its own story. After a 44% drawdown from $156, an miss of -51.6% in Q1 and halved adjusted net income in Q2 [8][9], sell-side framing anchors near 34x next year's estimates and treats the margin reset as management overreach. The settled assumption is that the NOP flywheel commoditized into an airline with a device attached.

Alpha-gap assessment

Mildly underpriced, but for an unglamorous reason. The crowd anchors on a 23.2x trailing multiple that is arithmetically fake: $82.8M of FY2025 net income was a deferred-tax valuation-allowance release, so genuine trailing earnings power is nearer $68M and roughly 50x. Yet the same crowd prices twenty-two owned aircraft and 86% internal mission coverage as cost inflation rather than as a chokepoint requiring years to replicate. Both errors partly cancel; the residual favours patient holders.

Convergence catalyst

The first quarter printing adjusted back above 16%, most plausibly in late 2027 as PAD Aviation integration costs annualize and internal air coverage passes 90%. The observable first sign is service gross margin expanding sequentially while service revenue share holds steady, proving logistics scales rather than dilutes.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.3
Expected volatility regime: high_erratic
Convergence-cycle position: reversal

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Owning THE Airplanes IS THE MOAT	TransMedics flies roughly 86% of its own NOP missions across twenty-two owned aircraft [2], a chokepoint no perfusion rival can replicate in under three years. That control converts each liver into disposable plus logistics revenue and secures organ-availability windows competitors cannot match, which explains 84.8% share of US ex-situ liver machine perfusion [1]. The advantage persists because fleet density compounds: more missions, lower cost per mission.	Not available	+35.0%
THE DCD Volume TIDE Keeps Rising	US donation-after-circulatory-death procurement continues expanding structurally, and DCD organs are precisely the marginal grafts requiring perfusion to be transplantable. US OCS transplant revenue rose $59.8M to $350.6M in the six months to 30 June 2026 on higher liver disposable volumes [4]. With 5,139 NOP transplants completed in 2025 against a 30,000-case 2032 ambition [6][7], penetration remains early enough to absorb several years of compounding.	Not available	+25.0%
Investment YEAR NOT Permanent Ceiling	The 2026 margin collapse is dominated by discretionary spending: adjusted operating expenses up roughly 46% and R&D up 98.5% year on year [2][3], against an aviation fixed base already largely built. As mission density rises across the same fleet, depreciation and crew cost per flight fall mechanically. Management targets operating margins approaching 30% later in the decade [10]; even partial delivery restores substantial earnings power by 2029.	Not available	+20.0%
SELF Funded Growth NO Dilution Needed	Roughly $473M of cash plus $18M restricted at 30 June 2026 [2] lets management fund OCS Kidney, Gen 3.0, ENHANCE and European expansion internally, at a share price 44% below its high where equity issuance would be punitive. That optionality carries real value: smaller perfusion competitors must raise capital into a 4% funds rate. The buffer persists while free cash flow stays positive, which TTM $79M supports.	Not available	+10.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Airline Economics EAT Device Margins	Service revenue reached 41% of Q2 2026 sales and grew 28.6% versus 15.7% for product [3], so the faster-growing line carries the lower margin. Gross margin fell 180bp year on year to 59.6% while adjusted operating income dropped 29.5% to $25.8M [3]. Jet fuel with Brent above $100 worsens it. Unless logistics scales into genuine leverage, mix dilution structurally caps the terminal margin investors will underwrite.	Not available	-20.0%
FIVE Percent Discount RATE 2032 Promise	The Fed's September 2026 hike to 3.75%-4.00% and a 5.00% ten-year Treasury are punishing for a stock whose value sits in a $2B-by-2032 revenue target [7]. Long-duration medtech multiples compress mechanically as the risk-free rate rises; TMDX already de-rated from 62x 2024 earnings toward a low-twenties trailing multiple flattered by a tax release. This persists until the inflation path permits easing, plausibly not before 2028.	Not available	-18.0%
IN SITU Perfusion Needs NO Flight	Normothermic regional perfusion reconditions DCD livers inside the donor, delivering six-month ischaemic cholangiopathy of 1.2% versus 9.5% for cold storage [13], at far lower cost, and consumes no TransMedics disposable and no TransMedics flight. One UK centre already sources 37.5% of liver transplants via NRP plus ex-situ perfusion [14]. Each converted US centre removes both revenue legs simultaneously, capping NOP pull-through economics.	Not available	-15.0%
Washington Rewrites THE Transplant Ruleb	HRSA rulemaking under the 2023 Securing the OPTN Act would make critical OPTN policies directly enforceable by the HHS Secretary [11], and the Board approved stricter DCD donor protections [12]. TransMedics volume is disproportionately DCD-driven, so process friction, OPO decertification churn and CMS review throttle case throughput. Management itself calls 2026 a chop year for exactly this reason [10]; the transition extends well into 2027.	Not available	-12.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Kidney Unlocks A Second Franchise	OCS Kidney is in pre-IDE discussions with FDA with first clinical experience targeted for 2027, addressing a US market exceeding 21,000 transplants annually [7], several times the liver pool served today. A successful IDE, pivotal readout and 2029-2030 commercialization would attach the existing aviation network to a far larger organ, lifting fleet utilization without proportional capex and re-rating terminal revenue. It stays below 50% because IDE timing, trial design and kidney's weaker ischaemic-injury rationale all remain unresolved at this cutoff.	35.0%	+60.0%
Strategic Medtech Takes IT OUT	A large-cap medtech or a Japanese acquirer already active in organ perfusion could bid for a uniquely defensible transplant logistics network trading 44% below its high with only 40.7M shares outstanding. The trigger would be a 2027-2029 stretch in which margins recover but the multiple does not, making the asset cheap relative to strategic value. Probability stays modest: founder-led governance, an unconventional owned-aviation business and antitrust scrutiny of perfusion concentration all deter bidders.	18.0%	+55.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Safety Signal Weaponized	An adverse registry or FDA signal on machine-perfused graft outcomes would be existential for pricing power. Registry data already show eight of nine 90-day graft failures among 545 NMP livers occurred on TransMedics devices [1] - unadjusted and confounded, but exactly the datapoint a short seller or plaintiff firm can amplify, as Scorpion Capital did in January 2025 [15][16]. A confirmed signal during 2027-2029 would stall centre adoption and collapse both volume and multiple.	22.0%	-40.0%
Convertible Settled FROM Weakness	Convertible notes maturing in 2028 carry a conversion price well above today's $86.40, so a share price still below it forces cash settlement or refinancing at 2028 credit spreads rather than costless conversion. With capital committed to aircraft and R&D nearly doubled [2], the buffer could prove insufficient, prompting a dilutive equity raise near cyclical lows. It stays under 50% because roughly $473M of cash and positive free cash flow provide genuine coverage.	30.0%	-25.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_4b9bb075-8b4c-508b-90e8-5bd08e77a1b2__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-6.0%	81.23	The early-November Q3 print lands in a seasonally soft transplant quarter with management already framing 2026 as a chop year; a five-percent ten-year yield further compresses the multiple on a 2032 revenue promise.
2	March 18, 2027	+7.0%	86.92	Q4 results and FY2027 guidance mark the margin trough. Adjusted operating margin guided back above fifteen percent as PAD integration costs annualize restores confidence that the investment year was deliberate and temporary.
3	June 18, 2027	+5.0%	91.27	First OCS Kidney clinical experience and initial European tender participation convert roadmap into evidence. Liver volume reacceleration lifts higher-margin disposable mix, and the market re-rates genuine cash earnings modestly upward.
4	September 18, 2027	-4.0%	87.62	Summer volume seasonality collides with HRSA enforcement rulemaking on DCD protocols, slowing OPO throughput. Investors mark down near-term case counts while the 2028 convertible maturity moves into active focus.
5	December 18, 2027	+8.0%	94.63	Refinancing clarity on the 2028 notes removes the dilution overhang. Q3 delivers a service gross-margin beat as internal air coverage exceeds ninety percent, materially cutting third-party charter expense per mission.
6	March 18, 2028	+6.0%	100.30	FY2028 guidance restores twenty-percent-plus growth with operating margin above eighteen percent. Kidney IDE progress and European revenue crossing a meaningful threshold widen the addressable narrative beyond US liver dependence.
7	June 18, 2028	-5.0%	95.29	Convertible settlement consumes cash or issues shares near the conversion price, while NRP adoption headlines at major US liver centres revive substitution fears. Both compress the multiple simultaneously.
8	September 18, 2028	+7.0%	101.96	Post-settlement balance-sheet clarity combines with a strong heart and lung quarter. Fed easing as inflation normalizes lowers the discount rate applied to long-duration medtech growth, supporting valuation recovery.
9	December 18, 2028	+6.0%	108.08	Operating leverage becomes visible: revenue passes $1.1B with fleet depreciation amortized across far more missions, lifting incremental margins and pushing free cash conversion above twenty percent of revenue.
10	March 18, 2029	+5.0%	113.48	FY2029 guidance embeds kidney pilot revenue for the first time. The European logistics hub reaches operating scale, diversifying a revenue base that was almost entirely United States through 2026.
11	June 18, 2029	+4.0%	118.02	A steady compounding quarter. Disposables mix stabilizes as OCS Gen 3.0 ships, restoring gross margin toward the mid-sixties and supporting a modestly higher earnings multiple on cleaner profits.
12	September 18, 2029	-4.0%	113.30	Seasonal softness meets a CMS reimbursement review of NOP service billing. Pricing scrutiny on transport economics trims forward margin assumptions across sell-side models and triggers profit-taking after four positive quarters.
13	December 18, 2029	+6.0%	120.10	The reimbursement outcome proves manageable. Q3 results confirm mid-teens volume growth with operating margins near twenty-five percent, and buy-side models begin extending the 2032 two-billion-dollar revenue target.
14	March 18, 2030	+5.0%	126.10	The target of doubling US NOP cases by 2030 tracks on plan. A kidney commercialization decision approaches while incremental capital intensity falls as the owned aircraft fleet stops expanding.
15	June 18, 2030	+4.0%	131.14	Free cash flow inflects decisively as capex-to-revenue drops below eight percent. Management signals a first capital-return framework, shifting the conversation from growth funding to per-share shareholder economics.
16	September 18, 2030	-3.0%	127.21	Law of large numbers bites: growth decelerates toward the mid-teens, prompting multiple compression even as absolute earnings rise. Competing perfusion entrants price disposables aggressively into mature liver centres.
17	December 18, 2030	+5.0%	133.57	Kidney approval or broad clinical launch adds a genuinely new revenue pool attached to existing aviation capacity. Earnings upgrades outweigh the deceleration discount into year-end institutional positioning.
18	March 18, 2031	+4.0%	138.91	Guidance consolidates a mature-growth profile: high-teens revenue growth, high-twenties operating margin, and meaningful buyback capacity funded from accumulated cash rather than new borrowing.
19	June 18, 2031	+3.0%	143.08	Incremental compounding with little narrative change. Valuation converges toward a low-twenties multiple on genuine, non-tax-flattered cash earnings, removing the accounting distortion that defined the 2025-2026 debate.
20	September 18, 2031	+3.0%	147.37	The horizon closes with TransMedics established as the transplant logistics utility. Returns now track earnings growth rather than re-rating, absent a new organ franchise or a strategic approach.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Real‐World Use of Normothermic Machine Perfusion in Liver Transplantation: A Multi‐Institutional Experience From the National Organ Perfusion Registry - PMCpmc.ncbi.nlm.nih.gov
[2]Transmedics Group (TMDX) Q2 2026 Earnings Report - Results, Call & Slides - TipRanks.comtipranks.com
[3]TransMedics Q2 2026 slides: revenue hits record but margins compress By Investing.cominvesting.com
[4]TransMedics Group, Inc. - Form 10-Q - FY2026sec.gov
[5]TMDX Q2-2026 Earnings Call - Alpha Spreadalphaspread.com
[6]transmedics reports fourth quarter and full year 2025 financial resultsbarchart.com
[7]TransMedics Group Inc (TMDX) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...finance.yahoo.com
[8]Earnings call transcript: TransMedics Q1 2026 earnings miss sends stock tumbling By Investing.cominvesting.com
[9]Why TransMedics Stock Is Sinking Today | The Motley Foolfool.com
[10]TransMedics at 2026 Global Healthcare Conference: growth plan widens By Investing.cominvesting.com
[11]Modernizing the Transplant System Through Safety and Transparency | HRSAhrsa.gov
[12]Building a Safer, More Accountable Transplant System | HRSAhrsa.gov
[13]Thoracoabdominal Normothermic Regional Perfusion: Real-world Experience and Outcomes of DCD Liver Transplantationncbi.nlm.nih.gov
[14]From Haphazard to a Sustainable Normothermic Regional Perfusion Service: A Blueprint for the Introduction of Novel Perfusion Technologiesncbi.nlm.nih.gov
[15]TMDX STOCK NEWS: TransMedics Group, Inc. 30% Stock Drop Prompts Fraud Investigation; Contact BFA Law if You Suffered Losses (NASDAQ:TMDX)globenewswire.com
[16]TMDX FRAUD ALERT: TransMedics Group, Inc. Investigated for Securities Fraud after Stock Drops 30% – Investors Urged to Contact BFA Law (NASDAQ:TMDX)globenewswire.com
[17]TransMedics Group (TMDX) Stock Price & Overviewstockanalysis.com
[18]TransMedics Group Inc (TMDX) Stock Price & News - Google Financegoogle.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Universal Investor — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.